CD20/CD30 CAR-T for relapsed lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of CAR-T cell therapy that targets both CD20 and CD30 proteins on lymphoma cells. It is for people whose lymphoma has returned or not responded after multiple treatments, including stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- Your lymphoma has returned or not responded to at least two standard treatments, including possibly a stem cell transplant.
- Your lymphoma must test positive for CD20, CD30, or both markers.
- Your heart, lungs, kidneys, and liver must work well enough (no serious heart disease, adequate oxygen levels).
- You cannot have active infections requiring IV antibiotics, or active central nervous system disease like brain lymphoma or seizures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
This trial tests a new CAR-T cell therapy that targets two proteins (CD20 and CD30) on lymphoma cells. It is for people whose lymphoma has come back or not responded to other treatments, including previous stem cell transplants. The goal is to see if this treatment is safe and helps shrink or control the lymphoma.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This trial tests a new type of CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) for people with B-cell lymphomas that have come back or not responded to standard treatments. It aims to see if this new manufacturing method is safe and effective.
This trial tests a new type of immunotherapy called CD30 CAR-T cells for people with CD30-positive lymphoma that has come back or hasn't responded to other treatments. The treatment uses your own immune cells that are specially trained to find and kill lymphoma cells carrying the CD30 marker.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.